Douglas S. Ingram - 16 Dec 2025 Form 4 Insider Report for ARROWHEAD PHARMACEUTICALS, INC. (ARWR)

Reporting relationship: Director
Issuer ticker: ARWR
Reported as of: 16 Dec 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 18 Dec 2025, 18:39:56 UTC
Prior SEC filing: 09 Dec 2025
Next SEC filing: 10 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/Doug Ingram

Key filing fact

Douglas S. Ingram filed Form 4 for ARROWHEAD PHARMACEUTICALS, INC. (ARWR) on 18 Dec 2025.

Key facts

This page summarizes Douglas S. Ingram's Form 4 filing for ARROWHEAD PHARMACEUTICALS, INC. (ARWR).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 18 Dec 2025, 18:39.

Change

Previous filing in this sequence was filed on 09 Dec 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001190644 Primary reporting owner

INGRAM DOUGLAS S

Relationship: Director
Address: 177 EAST COLORADO BLVD, SUITE 700, PASADENA
Signature: /s/Doug Ingram
Signature date: 18 Dec 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ARWR transaction

Common Stock

Award

Transaction value: $0
Shares: +7,819
Change %: +20%
Price: $0.000000
Shares after: 46,215
Date: 16 Dec 2025
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Represents shares underlying restricted stock units, which shares will vest in one installment on the first anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer on such date.